At the recently concluded congress of the European Hematology Association, researchers at Cogent Biosciences Inc. presented preclinical data on CGT-1145, a JAK2 V617F-mutant-selective inhibitor designed to preferentially target the mutant kinase while sparing wild-type JAK2.
IBI-3032 is a nonpeptide GLP-1 receptor agonist under development at Innovent Biologics Co. Ltd. for the potential treatment of obesity and other metabolic diseases. The company recently reported results of preclinical studies in which pharmacokinetic profiling was performed in vivo in different species, and the candidate’s in vivo efficacy was tested in a murine model with diet-induced obesity.
Integrin alpha-5 (ITGA5) is a central modulator of extracellular matrix signaling and has been tied to fibrosis and tissue damage, contributing to lupus nephritis (LN) pathogenesis. A group of researchers aimed to investigate the association between ITGA5 and LN and its inhibition as a potential strategy to improve renal outcomes.
Researchers from Innovent Biologics (Suzhou) Co. Ltd. presented preclinical efficacy data on IBI-3040, a dual agonist of amylin and calcitonin receptors (CTR). In vitro studies in UM-UC-3 cells expressing human CTR and amylin receptor subtypes AMY-1 and AMY-3 showed that IBI-3040 elicited robust receptor activation, as evidenced by cAMP accumulation assays.
Clinical evidence supports the integration of dual amylin and calcitonin receptor agonism (DACRA) with GLP-1, GIP and glucagon receptor signaling (triple G) as a synergistic approach for appetite modulation, insulin sensitivity and weight loss. Oban Biopharma Inc. is developing OBT-676, an oral small molecule that delivers full DACRA activity with triple G partial agonism for the treatment of metabolic disorders.
INHBE encodes the hepatokine activin E, a key mediator of liver-adipose crosstalk involved in the regulation of lipid metabolism and energy balance. Researchers from Innovent Biologics Co. Ltd. recently released preclinical efficacy data on IBI-3046, a novel RNAi therapeutic targeting INHBE.
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable feature of aging. Certainly, it is near universal in those older than 60. CH is not itself a disease, but 1%-2% of CH cases progress to acute myeloid leukemia, and it raises the risk of some other types of cancer as well. A total of eight genes are responsible for 95% of CH cases, George Vassiliou told the audience in Saturday’s plenary session at the 2026 Annual Congress of the European Hematology Association (EHA 2026).
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into cancer cells,” Franck Bourdeaut told his audience at the 2026 Annual Congress of the European Hematology Association (EHA 2026). “On the contrary, in pediatric cancers, it is assumed that very few mutations are responsible for a maturation block, make these cells derail from their normal differentiation trajectory and ultimately result in an early onset typical pediatric cancer.”
Researchers from Medizinische Hochschule Hannover and collaborators thus aimed to elucidate signaling adaptations following MAPK pathway inhibition in BRAFV 600E mutant cholangiocarcinoma (CCA) by generating a BRAF V600E-driven model of CCA.
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways involving complement factor 5 and its receptor (C5aR1) were overexpressed, and that a C5aR1 antagonist, avacopan, reduced the need for glucocorticoids and improved renal recovery. This led researchers to investigate the association of anti-C5aR1 antibodies with GCA and its outcomes.
RSS
